TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02712905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB059872
Description: Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.~INCB059872 tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB059872
Description: Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.~INCB059872 tablets to be administered by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid (ATRA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Study: NCT05808777

Intervention type: OTHER
Intervention: Phone interview
Description: A interview follow-up with a physician by phone was performed at 12 months after the onset of ICH.
Study: NCT01445600

Intervention type: DRUG
Intervention: ALTARGO(retapamulin)
Description: Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Study: NCT03683823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention guidance
Description: Explicitly guiding attention towards faces during public speaking exposures

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: Public speaking exposures
Study: NCT00656097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CL184
Description: CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HRIG
Description: HRIG 20 IU/kg intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching CL184
Description: Placebo intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
Study: NCT04237870

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active cTBS
Description: Active cTBS treatment will be delivered at an intensity that is 70% of the resting motor threshold (RMT). cTBS consist of bursts of 3 magnetic pulses at 30 Hz repeating every 200 ms for 300 pulses. cTBS will be repeated twice with 15 min interval. The cTBS sessions last for 4 weeks, 5 times a week. Treatment will be applied to central suleus.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham stimulation will be delivered using the same stimulation parameters and at the site of active treatment, but with only the side-edge resting on the scalp. The coil will be angled 45 degrees way from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g. contraction of scalp muscles) similar to those of active stimulation, but with minimal direct brain effects.
Study: NCT02770417

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: beta-alanine
Description: Patients receive beta-alanine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients receive placebo

Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: Healthy controls will be assessed to compare baseline muscle carnosine levels
Study: NCT05010239

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30-minute Mindfulness-Based Supportive Therapy
Description: The MBST consists of a session that involves interviewing patients with open-ended questions on suffering experiences. During the session, the practitioner will practice mindful breathing simultaneously while listening to patients. The practitioner will acknowledge the distress of patients when it is appropriate, but without losing their attention on mindful breathing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 30-minute supportive listening
Description: Patients in the control group will receive a 30-minute supportive listening session by a palliative care physician who has no experience in mindfulness practice. The session involves interviewing patients with the same open-ended questions on suffering experiences. The practitioner will acknowledge the distress of patients when it is appropriate. Outcomes will be measured at baseline and at minute 30.
Study: NCT02877888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoride varnish 22600ppm
Description: topical application on teeth every 6months
Study: NCT01540864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP404
Description: Administered orally once daily for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP404
Description: Administered orally once daily for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily for 26 weeks
Study: NCT01307657

Intervention type: OTHER
Group type: OTHER
Intervention: high fat meal
Description: Clopidogrel 600 mg loading dose at 8 am and high-fat meal at 12 pm
Study: NCT01781078

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImageReady System implant
Description: Pacemaker and lead(s) implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ImageReady System implant
Description: Pacemaker and lead(s) implant
Study: NCT03588559

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Pressure Measurement
Description: Measurement blood pressure by Transtek BPM TMB-1591-A-002 and reference device.
Study: NCT01541098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyophilized Plasma
Description: Licensed plasma that has been lyophilized.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed Plasma
Description: Plasma that has been authorized for transfusion.
Study: NCT01420887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Passive Motion
Description: Continuous passive motion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy.
Study: NCT04839952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles
Description: 12 telehealth sessions. The first 5 visits include psycho/medical education plus a motivational interviewing component. The second 7 sessions include psycho/medical education plus a problem solving training component.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education-Only Control
Description: This control condition includes meeting with a clinician for one telehealth visit to review nutrition and physical activity recommendations.
Study: NCT02079480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching with BMS-986090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keyhole limpet hemocyanin
Study: NCT04094168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEL NIDO CARDIOPLEGIA
Description: Del Nido components: Plasmalyte 148 (1000 ml), NaHCO3 8.4% 1M (13 ml), MgSO4 0,5 M (16,5 ml), Mannitol 20% (16,3 ml), KCl 2 M (13 ml), Lidocaine 2% (6,5 ml).~Electrolytic composition (l000 ml): Na+ 153 mEq, K+ 31 mEq, Cl - 124 mEq, Mg2+ 19,5 mEq, NaHCO3 13 mEq, Acetate 27 mEq, Sulfate 16,5 mEq, Gluconate 23 mEq.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COLD BLOOD BASED CARDIOPLEGIA
Description: Cardibraun components: Electrolytic composition (1000 ml): Na+ 185,8 mmol, K+ 24,1 mmol, Cl- 192,8 mmol, Acetate 23 mmol, Fosfate 0,97 mmol, Citrate 6,32 mmol.
Study: NCT02111317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verapamil
Description: oral
Study: NCT00003489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02866630

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Six additional blood samples will be taken from in-situ catheters during heart surgery

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Six additional blood samples will be taken from in-situ catheters during heart surgery
Study: NCT02457988

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivify Kit
Description: home telemonitoring devices with vital sign capturing capabilities, i.e. blood pressure, weight, pulse, and specific questionnaires targeted to the cirrhosis diagnosis.
Study: NCT01081132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Guanfacine Hydrochloride
Description: The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on weight.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be provided as 1,2,3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on weight.
Study: NCT02019667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGS-742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01935973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprosertib
Description: Given PO
Study: NCT04425304

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group counseling
Description: 4 times

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group counseling
Description: 4 times

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive group counseling
Description: 14 times

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive group counseling
Description: 14 times

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persuasive ICT support
Description: Weekly reminders for 12 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persuasive ICT support
Description: Weekly reminders for 12 months
Study: NCT03893669

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607
Description: 1 dose, 0.5ml, Intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agrippal
Description: 1 dose, 0.5ml, Intramuscular (IM) injection
Study: NCT04385108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection on admission and longitudinally
Description: 33 mL of blood collected on admission (day 0) and longitudinally (day 4, 8 12 and in discharge)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood collection on their first consultation and 10 to 14 days later
Description: 33 mL of blood collected on their first consultation and 10 to 14 days later
Study: NCT00728494

Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: Peginterferon alfa-2b will be administered according to the product's labeling.

Intervention type: BIOLOGICAL
Intervention: PegIntron (peginterferon alfa-2b; SCH 54031)
Description: Peginterferon alfa-2b will be administered according to the product's labeling.

Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Ribavirin will be administered according to the product's labeling.

Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Ribavirin will be administered according to the product's labeling.

Intervention type: BEHAVIORAL
Intervention: Patient Assistance Program
Description: The patient assistance program includes the following:~* Training by physicians or specialized nurses.~* Informational materials based on the To beat HCV program.~* Management of specific side effects.
Study: NCT00914147

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pulmonary function testing
Description: After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization.
Study: NCT04100616

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention for this study
Study: NCT04619797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 milligrams per square meter (mg/m\^2), administered by IV infusion, Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 milligrams per square meter (mg/m\^2), administered by IV infusion, Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin at dose of area under the concentration-time curve (AUC) of 5, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at dose of area under the concentration-time curve (AUC) of 5, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiragolumab Matching Placebo
Description: Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab at a fixed dose of 200 mg, administered by IV infusion, Q3W, on Day 1 of each 21-day cycle.
Study: NCT01861067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LESS-TLH

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LESS-LAVH
Study: NCT02539069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chondron Implantation
Description: In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
Study: NCT02731196

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Early versus later stabilization and neurodynamic exercise intervention following a post-op lumbar microdiscectomy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Early versus later stabilization and neurodynamic exercise intervention following a post-op lumbar microdiscectomy
Study: NCT01963702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study: NCT03826017

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Catechin high contain greentea extract
Description: Catechin high contain greentea extract 260 mg/day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks.
Study: NCT01719250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02271113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1271

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Sodium (Lovenox®)
Study: NCT02256098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATTUNE™ Knee Prosthesis by DePuy
Description: Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC Sigma Knee Prosthesis by DePuy
Description: Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
Study: NCT05704816

Intervention type: OTHER
Intervention: Spinal anesthesia application
Description: The success of the needles with different tip designs and thicknesses used in spinal anesthesia application

Intervention type: OTHER
Intervention: Spinal anesthesia application
Description: The success of the needles with different tip designs and thicknesses used in spinal anesthesia application

Intervention type: OTHER
Intervention: Spinal anesthesia application
Description: The success of the needles with different tip designs and thicknesses used in spinal anesthesia application

Intervention type: OTHER
Intervention: Spinal anesthesia application
Description: The success of the needles with different tip designs and thicknesses used in spinal anesthesia application

Intervention type: OTHER
Intervention: Spinal anesthesia application
Description: The success of the needles with different tip designs and thicknesses used in spinal anesthesia application

Intervention type: OTHER
Intervention: Spinal anesthesia application
Description: The success of the needles with different tip designs and thicknesses used in spinal anesthesia application
Study: NCT04345276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir+Ritonavir
Description: Danoprevir 100mg , one tablet each time , twice per day, up to 10 days. Ritonavir 100mg, one tablet each time , twice per day, up to 10 days.
Study: NCT01559662

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugared Chewing Gum (Juicy Fruit)
Description: One stick of gum, 3 times daily from Postoperative day 1 to 7
Study: NCT03717597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Subjects will attend a series of 2 hour classes, once a week for 10 weeks. Topics discussed in group sessions will cover compensation strategies (e.g., calendar, goal setting and task lists, functional zones) and brain health behaviors (e.g., exercise, cognitive activity, stress reduction and mindfulness).~Subjects may be asked to wear an actigraphy monitor (that looks like a wrist watch) and/or heart rate sensor that is designed to collect information regarding physical activity.
Study: NCT02280252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
Study: NCT02035566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehome Care Monitoring
Description: Telehome care monitoring over a 60-day period wherein patients transmit health measurements to their health care professional on a daily basis